Biomerieux SA
PAR:BIM
Biomerieux SA
EPS (Diluted)
Biomerieux SA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomerieux SA
PAR:BIM
|
EPS (Diluted)
€3
|
CAGR 3-Years
-10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
EPS (Diluted)
€0
|
CAGR 3-Years
-112%
|
CAGR 5-Years
-124%
|
CAGR 10-Years
-10%
|
|
|
Carmat SA
PAR:ALCAR
|
EPS (Diluted)
-€1
|
CAGR 3-Years
18%
|
CAGR 5-Years
21%
|
CAGR 10-Years
11%
|
|
|
Biosynex SA
PAR:ALBIO
|
EPS (Diluted)
-€3
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
|
Visiomed Group SA
PAR:ALVMG
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Biomerieux SA
Glance View
In the world of clinical diagnostics, bioMérieux SA emerges as a formidable player, weaving together a tapestry of innovation, precision, and reliability. Founded in 1963 by Alain Mérieux, the company has its roots deeply embedded in Lyon, France, where a legacy of scientific prowess meets a global vision. bioMérieux specializes in in vitro diagnostics, creating a broad array of products and solutions that essentially serve as the medical community’s early warning systems. Their expertise spans across fields like microbiology, immunoassays, and molecular biology, where they craft diagnostic kits and automated instruments that empower healthcare providers to detect and prevent diseases with remarkable accuracy. By tapping into a robust network of research and development, bioMérieux collaborates with hospitals, laboratories, and public health organizations worldwide to address both routine and critical diagnostic needs. At the heart of bioMérieux’s business is its razor-sharp focus on infectious diseases, a sector that has seen accelerated growth in recent years, particularly with the advent of global health challenges such as the COVID-19 pandemic. The firm generates revenue through the sale of its diagnostic solutions and related services, offering comprehensive testing systems that include reagents and consumables, maintenance contracts, and training for laboratory professionals. Their continuous investment in innovation allows them to expand their product portfolio and tailor solutions to the evolving needs of the healthcare industry. By maintaining a pulse on global health trends and investing in cutting-edge technologies, bioMérieux not only secures its market position but also plays a crucial role in strengthening global public health infrastructure.
See Also
What is Biomerieux SA's EPS (Diluted)?
EPS (Diluted)
3.6
EUR
Based on the financial report for Dec 31, 2024, Biomerieux SA's EPS (Diluted) amounts to 3.6 EUR.
What is Biomerieux SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
12%
Over the last year, the EPS (Diluted) growth was 21%. The average annual EPS (Diluted) growth rates for Biomerieux SA have been -10% over the past three years , 10% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet